Compile Data Set for Download or QSAR
Report error Found 246 Enz. Inhib. hit(s) with all data for entry = 3267
TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395812(2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-y...)
Affinity DataEC50:  0.600nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395811(5-tert-butyl-3-[5-cyclopropyl-4-(cyclopropylmethox...)
Affinity DataEC50:  0.800nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395807(US10308659, Example 6 | US10308659, Example 9 | 3-...)
Affinity DataEC50:  1nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395922(3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyr...)
Affinity DataEC50:  1nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395804(3-cyclopropyl-5-[5-cyclopropyl-4-(cyclopropylmetho...)
Affinity DataEC50:  1.20nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395854(5-tert-butyl-3-[5-cyclopropyl-4-[(4-fluorophenyl)m...)
Affinity DataEC50:  1.40nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395866(5-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethox...)
Affinity DataEC50:  1.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395916(5-tert-butyl-3-[5-cyclopropyl-4-(2,2-difluoroethox...)
Affinity DataEC50:  2nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395924(3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethox...)
Affinity DataEC50:  2nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395878(5-tert-butyl-3-[5-cyclopropyl-4-(3,3-difluoropyrro...)
Affinity DataEC50:  2.10nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395805(3-cyclopentyl-5-[5-cyclopropyl-4-(cyclopropylmetho...)
Affinity DataEC50:  2.10nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395841(3-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroet...)
Affinity DataEC50:  2.20nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395843(5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-...)
Affinity DataEC50:  2.30nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395831(2-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluor...)
Affinity DataEC50:  2.60nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395828(2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-...)
Affinity DataEC50:  3.5nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395815(3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-y...)
Affinity DataEC50:  3.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395821((4S)-4-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylm...)
Affinity DataEC50:  3.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395915(5-tert-butyl-3-[6-chloro-5-cyclopropyl-4-(oxan-4-y...)
Affinity DataEC50:  3.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395823(2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-y...)
Affinity DataEC50:  4.20nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395864(5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyri...)
Affinity DataEC50:  4.30nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395825(3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-y...)
Affinity DataEC50:  4.30nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395875(5-tert-butyl-3-[5-cyclopropyl-4-(3,3,4,4-tetrafluo...)
Affinity DataEC50:  4.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395913(5-tert-butyl-3-(6-chloro-5-cyclopropyl-4-(4-fluoro...)
Affinity DataEC50:  4.80nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395871(US10308659, Example 70)
Affinity DataEC50:  5.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395862(5-tert-butyl-3-[5-cyclopropyl-4-(4-fluorophenoxy)p...)
Affinity DataEC50:  6.20nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395834(US10308659, Example 44 | US10308659, Example 33)
Affinity DataEC50:  6.90nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395856(5-tert-butyl-3-[5-cyclopropyl-4-[(3-methyloxetan-3...)
Affinity DataEC50:  7.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395833(5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-(3,3-difl...)
Affinity DataEC50:  8.60nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395880(5-tert-butyl-3-(5-cyclopropyl-4-pyrrolidin-1-ylpyr...)
Affinity DataEC50:  9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395870(2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-...)
Affinity DataEC50:  9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395867(2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-...)
Affinity DataEC50:  9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395807(US10308659, Example 6 | US10308659, Example 9 | 3-...)
Affinity DataEC50:  9.20nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395808(3-cyclopropyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroe...)
Affinity DataEC50:  11.1nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395891(5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethox...)
Affinity DataEC50:  11.8nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395894(5-tert-butyl-3-[5-cyclopropyl-4-(1-propan-2-ylpyrr...)
Affinity DataEC50:  11.9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395853(3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-triflu...)
Affinity DataEC50:  13.1nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395858(5-tert-butyl-3-[5-cyclopropyl-4-[[(2S)-1-methylpyr...)
Affinity DataEC50:  13.4nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395820(3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-y...)
Affinity DataEC50:  13.7nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395835(3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-...)
Affinity DataEC50:  14.7nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395917(5-tert-butyl-3-[5-cyclopropyl-4-(2-fluoroethoxy)py...)
Affinity DataEC50:  15.5nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395859(5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-2-ylmethox...)
Affinity DataEC50:  15.6nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395807(US10308659, Example 6 | US10308659, Example 9 | 3-...)
Affinity DataEC50:  15.8nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395834(US10308659, Example 44 | US10308659, Example 33)
Affinity DataEC50:  15.9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395829(3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-y...)
Affinity DataEC50:  16nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395890(5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxybutoxy)p...)
Affinity DataEC50:  16.2nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395863(5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)py...)
Affinity DataEC50:  17.8nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395849(5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-triflu...)
Affinity DataEC50:  19nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395898(5-tert-butyl-3-[5-cyclopropyl-4-[(1-methylpiperidi...)
Affinity DataEC50:  19nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395877(7-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopr...)
Affinity DataEC50:  19.3nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM395832(2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-...)
Affinity DataEC50:  19.4nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

Displayed 1 to 50 (of 246 total ) | Next | Last >>
Jump to: